New Drug Delivery Technologies for Better Treatments to be Presented by Catalent Experts at ICSE Japan

Three experts from Catalent Pharma Solutions are to present at the forthcoming ICSE Japan exhibition which takes place at Tokyo Big Sight, Tokyo, Japan, from 9–11 April.

On Wednesday 9 April, at 3.15 pm, Catalent’s Zydis Fast Dissolve Formulation Manager, Dr Keiko Tsutsumi, will present “New Local Development Facilities for Zydis, a World Leading Oral Dissolve Technology — Enabling Better Treatments.” Zydis is a unique, freeze-dried oral dosage form that disperses in the mouth, requiring no water. In some cases this can enhance the performance of a drug and can also contribute towards better patient compliance.

“Recent Softgel Innovations: Improving Delivery of More Molecules” is the title of Hironori Kubota, Director of Pharmaceutical Softgels' session on Thursday 10 April at 4 pm. Catalent has recently launched three new softgel products and his presentation will feature the potential patient benefits of OptiGel Micro, OptiGel Lock and OptiGel Bio. Amongst their many benefits these include easier advanced formulation for protein and peptide drugs, patient benefits such as easier swallowing and the opportunity for improved compliance, and abuse deterrence.

Finally, on Friday 11 April, commencing at 11.45 am, Shingo Nakamura, Director of Biologics, will discuss “Accelerated Biosimilar Development and Integrated Solutions for Better Treatments.” His presentation will feature an overview of Catalent’s GPEx cell line expression technology that produces high-yielding, stable mammalian cell lines and has been successfully applied in the manufacture of more than 500 different recombinant proteins, over 30 of which are now undergoing clinical trials or being supplied commercially.